Tekla Life Sciences Inves...

NYSE: HQL · Real-Time Price · USD
13.82
0.17 (1.25%)
At close: Aug 15, 2025, 3:59 PM
13.86
0.29%
After-hours: Aug 15, 2025, 05:16 PM EDT

Tekla Life Sciences Investors Income Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year Q4 2024 Q2 2024 Q4 2023 Q2 2023 Q4 2022 Q2 2022 Q4 2021 Q2 2021
Period Ending Sep 30, 2024 Mar 31, 2024 Sep 30, 2023 Mar 31, 2023 Sep 30, 2022 Mar 31, 2022 Sep 30, 2021 Mar 31, 2021
Revenue
3.98M 31.63M 31.49M 23.62M 31.86M 26.15M 45.01M 45.53M
Cost of Revenue
n/a 2.59M 2.59M 2.64M 5.55M 6.01M 6.08M 5.69M
Gross Profit
3.98M 29.04M 28.9M 20.98M 26.31M 20.14M 38.94M 39.84M
Operating Income
-1.92M -12.1M -12.39M -29.25M -104.61M -43.33M 64.53M 124.43M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
85.3M 38.81M 22.35M 5.5M -104.6M -43.31M 64.53M 124.41M
Net Income
85.3M 38.81M 22.35M 5.5M -104.6M -43.31M 64.53M 124.41M
Selling & General & Admin
5.9M 2.72M 2.87M 4.31M 1.44M 3.21K 3.21K 3K
Research & Development
n/a n/a n/a n/a n/a n/a n/a n/a
Other Expenses
n/a -38.42M -38.42M -47.35M -47.35M n/a n/a n/a
Operating Expenses
5.9M 41.14M 41.29M 17.82M 14.98M 54.77K 31.12K 61.04K
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
24.61K 8.11K n/a n/a n/a n/a n/a n/a
Cost & Expenses
5.9M 43.73M 43.88M 52.87M 136.47M 69.48M -19.51M -78.9M
Income Tax Expense
n/a -43.81K -43.81K n/a -843.92 -1.9K -2.07K -1.84K
Shares Outstanding (Basic)
28.77M 27.35M 26.79M 26.21M 25.68M 25.14M 24.67M 24.28M
Shares Outstanding (Diluted)
28.77M 27.35M 26.79M 26.21M 25.68M 25.14M 24.67M 24.28M
EPS (Basic)
3.06 1.41 0.86 0.19 -4.13 -1.69 2.64 5.21
EPS (Diluted)
3.06 1.41 0.86 0.19 -4.13 -1.69 2.64 5.21
EBITDA
100.51M 89.07M -11.45M -28.31M -104.61M -43.33M 64.53M 124.43M
EBIT
99.25M 89.07M -12.39M -29.25M -104.61M -43.33M 64.53M 124.43M
Depreciation & Amortization
1.92M 697.15K 984.56K 1.59M 651.98K 1.9K 2.07K 1.84K